Table 2.
Comparison of the baseline characteristics and clinical outcome according to the subcategorized groups of HT.
| Characteristics |
HI
n = 29 |
PH
n = 20 |
p -value |
|---|---|---|---|
| Sex (male), n (%) | 19 (65.5%) | 8 (40%) | 0.141 |
| Age, year, median (IQR) | 70.0 (59.0–78.0) | 73.5 (62.8–82.5) | 0.395 |
| Smoking, n (%) | 8 (27.6%) | 2 (10.0%) | 0.254 |
| Drinking, n (%) | 5 (17.2%) | 2 (10.0%) | 0.767 |
| Hypertension, n (%) | 18 (62.1%) | 13 (65.0%) | 1 |
| Diabetes mellitus, n (%) | 6 (20.7%) | 6 (30.0%) | 0.684 |
| History of stroke or TIA, n (%) | 4 (13.8%) | 1 (5.0%) | 0.604 |
| Coronary artery disease, n (%) | 7 (24.1%) | 3 (15.0%) | 0.675 |
| Atrial fibrillation, n (%) | 11 (37.9%) | 11 (55.0%) | 0.374 |
| TOAST, n (%) | |||
| LAA | 16 (55.2%) | 11 (55.0%) | 0.992 |
| CE | 9 (31.0%) | 6 (30.0%) | |
| ODC | 0 (0%) | 0 (0%) | |
| SUE | 4 (13.8%) | 3 (15.0%) | |
| Baseline SBP, mmHg, median (IQR) | 150 (131–160) | 148 (131–170) | 0.378 |
| Baseline DBP, mmHg, median (IQR) | 87.0 (78.0–95.8) | 80.0 (71.0–90.0) | 0.428 |
| Baseline NIHSS, median (IQR) | 13 (10–17) | 14 (13–18) | 0.556 |
| Baseline ASPECTS, median (IQR) | 10.0 (9.0–10.0) | 9.0 (8.0–10.0) | 0.122 |
| Glucose, mmol/L, median (IQR) | 7.45 (6.53–8.28) | 7.95 (6.18–9.48) | 0.462 |
| Leukocyte, ×109/L, median (IQR) | 8.83 (7.84–10.40) | 8.34 (5.48–11.86) | 0.394 |
| Platelet, ×109/L, median (IQR) | 171 (149–202) | 167 (147–205) | 0.527 |
| Hemoglobin, g/L, median (IQR) | 137 (132–148) | 134 (125–150) | 0.693 |
| PT, s, median (IQR) | 11.5 (10.9–12.1) | 11.0 (10.0–12.3) | 0.488 |
| APTT, s, median (IQR) | 25.8 (23.9–28.8) | 25.9 (20.9–27.8) | 0.352 |
| INR, median (IQR) | 1.00 (0.95–1.08) | 0.94 (0.91–1.10) | 0.379 |
| Fibrinogen, g/L, median (IQR) | 2.29 (1.86–2.78) | 2.50 (2.00–2.98) | 0.353 |
| D-dimer, mg/L, median (IQR) | 0.80 (0.42–2.07) | 1.83 (1.02–6.42) | 0.521 |
| Creatinine, μmol/L, median (IQR) | 84.0 (68.0–102.5) | 64.5 (50.5–92.0) | 0.394 |
| Urea, mmol/L, median (IQR) | 5.50 (4.50–7.00) | 6.10 (5.00–7.65) | 0.294 |
| Uric acid, μmol/L, median (IQR) | 321 (253–396) | 323 (221–467) | 0.380 |
| Potassium, mmol/L, median (IQR) | 3.82 (3.59–4.30) | 3.66 (3.39–4.10) | 0.527 |
| Sodium, mmol/L, median (IQR) | 140 (138–141) | 140 (137–143) | 0.255 |
| Chloride, mmol/L, median (IQR) | 103 (101–105) | 105 (103–106) | 0.495 |
| Troponin, ng/ml, median (IQR) | 0.01 (0–0.03) | 0.01 (0.01–0.02) | 0.754 |
| BNP, pg/ml, median (IQR) | 153 (31–382) | 233 (130–301) | 0.387 |
| Intravenous thrombolysis, n (%) | 9 (31.0%) | 9 (45.0%) | 0.487 |
| Anticoagulant agent, n (%) | 8 (27.6%) | 5 (25.0%) | 1 |
| T1, h, median (IQR) | 4.38 (3.75–7.15) | 5.51 (4.08–7.31) | 0.238 |
| T2, h, median (IQR) | 6.75 (5.33–8.83) | 7.25 (6.21–8.69) | 0.442 |
| T2–T1, h, median (IQR) | 1.60 (1.25–2.52) | 1.33 (1.17–2.24) | 0.466 |
| 3-month mRS (mRS ≥3), n (%) | 17 (58.6%) | 20 (100%) | 0.003* |
HT, hemorrhagic transformation; PH, parenchymal hematoma; HI, hemorrhagic infarction; IQR, interquartile range; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardioembolism; ODC, stroke of other determined cause; SUE, stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; BNP, B-type natriuretic peptide; T1, time from symptom onset to puncture; T2, time from symptom onset to vascular recanalization; T2–T1, time of mechanical thrombectomy treatment; mRS, modified Rankin Scale.
Bold* values indicate p < 0.05.